Clinical trials: Neoplasms, Metastatic
Advanced/Metastatic Breast Cancer
Study Of Sunitinib With Capecitabine In Breast Cancer
To evaluate efficacy, safety and pharmacokinetics of sunitinib plus Capecitabine in Japanese patients with advanced/metastatic breast cancer.
- Trial name
- NCT00662025
- Testing
- Capecitabine, Sunitinib
- Where
- 17 sites in Japan
- Volunteers
- 63 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumors
A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
This study is an open-label, multicenter, phase I/II study to evaluate the safety, PK and clinical efficacy of avapritinib in Chinese subjects with unresectable or metastatic GIST.
- Trial name
- NCT04254939
- Testing
- CS3007 (BLU-285)
- Where
- 16 sites in China
- Volunteers
- 65 people
- Sponsor
- CStone Pharmaceuticals
Metastatic Pancreatic Cancer
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
This study plans to enroll participants with previously treated metastatic pancreatic cancer and harbor centrally confirmed KRAS G12D mutation.
- Trial name
- NCT07262567
- Testing
- GFH375, Chemotherapy
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Metastatic Colorectal Cancer
Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)
This is an open-label, non-randomized, multicenter Phase II study evaluating folinic acid + fluorouracil + irinotecan (FOLFIRI) plus cetuximab (Erbitux) or folinic acid + fluorouracil + oxaliplatin (FOLFOX) plus cetuximab as…
- Trial name
- APEC (NCT00778830)
- Testing
- Cetuximab, FOLFIRI, FOLFOX
- Where
- Singapore
- Volunteers
- 289 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Cancer
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
This 4 arm study assessed the efficacy and safety of oral capecitabine (Xeloda) or intravenous (iv) fluorouracil/leucovorin, in combination with iv oxaliplatin (Eloxatin) with or without iv bevacizumab (Avastin), as a first-line…
- Trial name
- NCT00069095
- Testing
- Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg
- Where
- 236 sites in United States, Australia and 31 more
- Volunteers
- 2,035 people
- Sponsor
- Hoffmann-La Roche
Metastatic Breast Cancer
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
The aim of this study is to evaluate the efficacy and safety of ESG401 in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer.
- Trial name
- NCT06383767
- Testing
- ESG401, Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)
- Where
- China
- Volunteers
- 378 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Pain, Neoplasm Metastasis
Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases
This study will evaluate the safety and efficacy of cryoablation therapy for relief of pain associated with metastatic bone tumors.
- Trial name
- NCT01461265
- Testing
- Cryoablation
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 29 people
- Sponsor
- Boston Scientific Corporation
Advanced Solid Cancers
Study of SC-102 in Patients With Advanced Solid Tumors
This study will evaluate the safety, PK profile, and anti-cancer efficacy of SC-102 in subjects with advanced solid tumors
- Trial name
- NCT06710158
- Testing
- SC-102
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin ConjuStar Biologics Co., Ltd.
HPV-Related Squamous Cell Carcinoma
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers
This is a First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of HB-201 single vector therapy and HB-201 \& HB-202 two-vector therapy in patients with HPV 16+ confirmed cancers comprising two parts…
- Trial name
- NCT04180215
- Testing
- HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab.
- Where
- 34 sites in United States, Netherlands and 1 more
- Volunteers
- 198 people
- Sponsor
- Hookipa Biotech GmbH
Metastatic Colorectal Cancer
A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer.
This study aims to comprehensively identify the various treatment patterns of second- or subsequent-line palliative chemotherapy used in patients with metastatic colorectal cancer who have experienced failure of first-line…
- Trial name
- NCT07263178
- Testing
- Second and later-line palliative chemotherapy
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
The primary objective of the Phase II portion of this study is to assess the efficacy of KRN330 in combination with irinotecan after first-line or adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)/CapOx (capecitabine…
- Trial name
- NCT00838578
- Testing
- KRN330, Irinotecan
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Cancer, Solid Tumor
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.
- Conditions
- Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05704985
- Testing
- DK210 (EGFR), Radiation therapy, Immune checkpoint blockers
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- DEKA Biosciences
Melanoma, BRAF V600 Mutation
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations
The current commercially available MEKTOVI® (binimetinib) 15 mg tablets are provided as immediate release film-coated tablets for oral administration.
- Conditions
- Melanoma, BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma
- Trial name
- NCT05810740
- Testing
- Binimetinib 15 MG, Binimetinib 45 MG
- Where
- France
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament
Advanced Solid Tumor, Advanced Malignant Neoplasm
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C…
- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
- Trial name
- NCT04585750
- Testing
- rezatapopt, pembrolizumab
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- PMV Pharmaceuticals, Inc
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer
This single arm study will assess the efficacy and safety of Avastin in combination with Herceptin and Xeloda as first-line treatment of patients with HER2-positive locally recurrent or metastatic breast cancer.
- Trial name
- NCT00811135
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], trastuzumab [Herceptin]
- Where
- 35 sites in Denmark, France and 4 more
- Volunteers
- 88 people
- Sponsor
- Hoffmann-La Roche
Metastatic Pancreatic Cancer
Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
This clinical trial is an open label Phase II study of the combination of intravenously administered SGT-53 and gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer.
- Trial name
- NCT02340117
- Testing
- SGT-53, nab-paclitaxel, Gemcitabine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- SynerGene Therapeutics, Inc.
Colorectal Cancer
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have…
- Trial name
- STELLAR-303 (NCT05425940)
- Testing
- XL092, Atezolizumab, Regorafenib
- Where
- 133 sites in United States, Australia and 14 more
- Volunteers
- 901 people
- Sponsor
- Exelixis
Non-Small Cell Lung Cancer
A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
This is an open label phase I/phase II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, preliminary efficacy of Dositinib in participants of locally advanced or metastatic non-small cell lung cancer…
- Trial name
- NCT07231068
- Testing
- Dositinib mesylate tablets
- Where
- 5 sites in China
- Volunteers
- 153 people
- Sponsor
- Henan Genuine Biotech Co., Ltd.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the body from their original…
- Trial name
- NCT07213817
- Testing
- IPN60300
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 114 people
- Sponsor
- Ipsen
Melanoma
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
This is a two-arm, open-label, randomized Phase III study comparing single agent GSK1120212 to chemotherapy (either dacarbazine or paclitaxel) in subjects with Stage IIIc or Stage IV malignant cutaneous melanoma.
- Trial name
- NCT01245062
- Testing
- GSK1120212, Chemotherapy
- Where
- 112 sites in United States, Argentina and 17 more
- Volunteers
- 322 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.